Cipher Pharmaceuticals Inc. announced the Canadian launch of OZANEX™ (ozenoxacin cream, 1%), a novel bactericidal topical antibiotic cream indicated for the treatment of impetigo in patients aged 2 months and older. In two Phase III pivotal studies involving 875 adult and pediatric subjects, OZANEX demonstrated excellent antibacterial activity against Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant (MRSA) strains.